Vemurafenib: adverse event reports filed with FDA

3,866

reports as suspect product

0% of all reports · about 261 a year

59

reports, 12 months to June 2026

143 in the 12 months before

92.4%

marked serious by the reporter

70.8% across the class

12.9%

record death among outcomes, as reported

500 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Vemurafenib reports recording the termmedian drug in kinase inhibitor

1. Pyrexiafever7.8%303
2. Rashskin rash7.8%303
3. Disease progressionthe disease advanced6.8%264
4. Diarrhoealoose or frequent stools6.7%259
5. Arthralgiajoint pain5.5%212
6. Nauseafeeling sick5.1%198
7. Fatiguetiredness4.9%190
8. Off label useused for a purpose or in a way not on the label4.3%165
9. Photosensitivity reactionskin reaction to sunlight3.9%149
10. Vomitingbeing sick3.7%142
11. Anaemialow red blood cells3.5%137
12. Rash maculo-papulara rash of flat and raised spots3.2%124
13. Skin toxicity3%115
14. Acute kidney injurysudden loss of kidney function2.9%114
15. Deaththe patient died; cause not stated by this term2.9%114
16. Electrocardiogram QT prolongeda QT prolongation on the ECG2.9%114
17. Dyspnoeashortness of breath2.5%97
18. Astheniaweakness or lack of energy2.4%93
19. Decreased appetitereduced appetite2.4%93
20. Pneumonialung infection2.4%93
21. Headachehead pain2.3%87
22. Alopeciahair loss2.1%82
23. Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement2.1%82
24. Hyperkeratosis2%76
25. General physical health deteriorationgeneral decline in health1.9%74
26. Erythemaskin redness1.9%73
27. Alanine aminotransferase increasedraised liver enzyme (ALT)1.9%72
28. Squamous cell carcinoma1.9%72
29. Neutropenialow neutrophils, a type of white blood cell1.8%71
30. Aspartate aminotransferase increasedraised liver enzyme (AST)1.8%70

Top 30 of 608 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 100 drugs in the kinase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 849,161 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 23% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,866 reports.

Drugs most often listed in the same reports

Other products listed in reports where Vemurafenib is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the kinase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Vemurafenib as a suspect or interacting product; reports listing it only as a concomitant medication (171) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.